BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that Executive Chairman and Founder, Gabriele Cerrone will ring the Closing Bell at the Nasdaq MarketSite in Times Square, New York today. The ceremony, will be held from 3:45 PM to 4:15 PM ET, celebrates Tiz ...

LONDON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- RedCloud Holdings PLC (NASDAQ: RCT) ("RedCloud" or the "Company"), the technology company building an intelligent infrastructure for global trade, today announced that progress in 2025 has exceeded management expectations and positions the Company for accelerated growth and expansion in 2026. 2025 Performance The Company reaffirms its full-year revenue guidance of $51-53 million, marking the Company's strongest year on record. Growth was driven by expansion in exist ...

TORONTO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Emerita Resources Corp. (TSXV: EMO) (the “Company” or “Emerita”) announces that it will be petitioning the Administrative Court of Andalucia (Sección Primera Sala de lo Contencioso-Administrativo del Tribunal Superior de Justicia de Andalucia) (the “Administrative Court”) to complete its ruling with respect to the alleged irregularities in awarding the Aznalcollar public tender. The Company will not pursue an appeal of the recent criminal case (the “Criminal Case”) ...

Voting results of the Fiscal 2025 Annual General Meeting of Pluxee Amsterdam-Schiphol, December 17, 2025 // Pluxee N.V. (“Pluxee”) held today its Annual General Meeting of Shareholders, in Amsterdam-Schipol, chaired by Didier Michaud-Daniel, Executive Chair of Pluxee’s Board of Directors. All resolutions on the agenda were approved by the shareholders. This included the adoption of the financial statements for the fiscal year which ended on August 31, 2025 (“Fiscal 2025”), and of the dividend distribution ...

NEW YORK, Dec. 17, 2025 (GLOBE NEWSWIRE) -- AMC Robotics Corporation (Nasdaq: AMCI) (“AMC Robotics” or the “Company”), an AI-driven safety and robotics solutions company, today announced that it has established a non-binding supplier framework to support the deployment of its solutions for a government agency in Japan. The framework outlines a collaborative path to introduce AMC’s quadruped robotics platform and expand its capabilities for the Japanese market. This includes joint work on AI-powered security ...

Core Insights - Acrivon Therapeutics is a clinical stage biotechnology company focused on precision medicine through its proprietary Generative Phosphoproteomics AP3 platform, which enables the interpretation and quantification of drug-regulated effects in intact cells [2][3] Company Overview - Acrivon Therapeutics utilizes its Generative Phosphoproteomics AP3 platform to develop precision medicines, providing rapid and actionable insights from terabytes of proprietary data [2] - The platform includes tools such as the AP3 Data Portal, AP3 Kinase Substrate Relationship Predictor, and AP3 Interactome, allowing for advanced drug discovery beyond traditional methods [2] Clinical Programs - The lead program, ACR-368 (prexasertib), is a selective small molecule inhibitor targeting CHK1 and CHK2, currently in a Phase 2b trial for endometrial cancer, with Fast Track designation from the FDA [3] - ACR-2316, a second clinical stage asset, is a potent WEE1/PKMYT1 inhibitor showing promising early clinical activity and safety in a Phase 1 trial, with initial tumor shrinkage observed [4][6] Upcoming Updates - Acrivon plans to provide updates on ACR-368 and ACR-2316 clinical data via a conference call and webcast in January 2026, including interim data from ongoing trials and new preclinical candidates [1][6]

Core Viewpoint - YXT.com Group Holding Limited has filed a shelf registration statement with the SEC to offer and sell up to $100 million of its securities, providing the company with financial flexibility for future capital needs [2][3]. Company Overview - YXT.com is a technology company focused on AI-enabled enterprise productivity solutions, aiming to empower organizational development through technology [6]. - The company has a mission to enhance enterprise productivity by leveraging over a decade of experience in tech-enabled talent learning and development [6]. - YXT.com has received recognition from numerous Global and China Fortune 500 companies since its inception [6]. Registration Statement Details - The registration statement allows YXT.com to offer various types of securities, including Class A ordinary shares, preferred shares, warrants, subscription rights, and units [2]. - The company is not obligated to sell securities under the registration statement, and the terms of any offerings will be determined based on market conditions at the time of the offering [2][3]. - The registration statement has been filed but is not yet effective, meaning no securities can be sold or offered until it is declared effective by the SEC [3].

Core Insights - ASP Isotopes has received all necessary regulatory approvals for the acquisition of Renergen, allowing the scheme to proceed [1][2] - The acquisition aims to create a global leader in the production of critical materials, including helium and isotopically enriched gases, with significant synergies expected from 2026 [3][4] - Positive operational progress has been reported at Renergen's Virginia Gas Project, with a production update anticipated by the end of January 2026 [4] Company Overview - ASP Isotopes is focused on developing technology for isotope production, utilizing proprietary Aerodynamic Separation Process technology [5] - The company plans to enrich isotopes for various sectors, including healthcare, technology, and nuclear energy [5][6] - There is a growing demand for specific isotopes for applications in quantum computing and green energy [6] Acquisition Details - Renergen shareholders will receive 0.09196 new ASP Isotopes shares for each share held, as part of the acquisition scheme [1] - The implementation of the scheme will commence upon receipt of a compliance certificate from the South African Takeover Regulation Panel, expected around December 18, 2025 [2] - The merger is expected to create a vertically and horizontally integrated supply chain with substantial geographic and customer overlap [3]

Core Insights - SCHMID Group N.V. has secured a two-tranche term loan facility of up to €10 million to strengthen its financial structure and working capital [1][2] - The first tranche of €2.5 million is expected to be drawn on December 18, 2025, with the second tranche anticipated in early 2026 [2] - The company appointed Arthur Schuetz as the new Chief Financial Officer, effective January 1, 2026, bringing over 20 years of investment banking experience [3][4] Financial Structure - The term loan includes an optional equity conversion right at a fixed share price of USD 2.15 per share [1] - A related party loan raised an additional €200,000, involving the company's Chairman, Board members, and external investors [1] - The financing aims to convert strong order intake into revenues and optimize the company's capital structure for future opportunities [2] Leadership Changes - Arthur Schuetz will replace Julia Natterer as CFO, who will focus on daily operations at Gebr. Schmid GmbH [3] - Schuetz's background includes leading equity and debt capital fundraisings and managing complex cross-border M&A transactions [3][4] - The board expresses confidence in Schuetz's ability to enhance the company's financial strategy and stakeholder value [4] Company Overview - SCHMID Group is a global leader in high-tech electronics, photovoltaics, glass, and energy systems, headquartered in Freudenstadt, Germany [7] - The company employs over 800 staff and operates technology centers and manufacturing sites in Germany and China [7] - It focuses on customized equipment and process solutions, ensuring high technology levels and sustainability in production processes [7]

Core Viewpoint - Kyverna Therapeutics, Inc. has announced a public offering of 13,333,333 shares at a price of $7.50 per share, aiming to raise approximately $100 million before expenses [1][2]. Company Overview - Kyverna Therapeutics is a clinical-stage biopharmaceutical company focused on developing cell therapies for autoimmune diseases, with its lead candidate being miv-cel, an autologous CD19-targeting CAR T-cell therapy [5][6]. Offering Details - The public offering is expected to close on or about December 18, 2025, pending customary closing conditions [1]. - The underwriters have a 30-day option to purchase up to 1,999,999 additional shares at the public offering price [1]. Management and Underwriters - J.P. Morgan, Leerink Partners, Morgan Stanley, and Wells Fargo Securities are acting as joint book-running managers for the offering [2].